Get the Stockscreener App
60.73
3.66%
-2.31
After Hours:
61.51
0.78
+1.28%
Metsera Inc stock is traded at $60.73, with a volume of 4.90M.
It is down -3.66% in the last 24 hours and up +17.01% over the past month.
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
See More
Previous Close:
$63.04
Open:
$61.1
24h Volume:
4.90M
Relative Volume:
2.20
Market Cap:
$6.38B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+16.45%
1M Performance:
+17.01%
6M Performance:
+136.76%
1Y Performance:
+0.00%
1-Day Range:
$60.37
$61.85
1-Week Range:
$51.84
$66.10
52-Week Range:
$12.30
$66.10
Metsera Inc Stock (MTSR) Company Profile
Name
Metsera Inc
Sector
Industry
Phone
(212) 784-6595
Address
3 WORLD TRADE CENTER, NEW YORK
Compare MTSR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
60.73 | 6.63B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-25 | Initiated | Leerink Partners | Outperform |
| Jun-20-25 | Initiated | Wells Fargo | Overweight |
| Feb-25-25 | Initiated | BofA Securities | Buy |
| Feb-25-25 | Initiated | Evercore ISI | Outperform |
| Feb-25-25 | Initiated | Guggenheim | Buy |
View All
Metsera Inc Stock (MTSR) Latest News
Key facts: Novo Nordisk Q3 revenue up 9.4%; bids $8.5B for Metsera; Hims launches semaglutide - TradingView
Why Pfizer Can Still Prevail in the Obesity Fight With Novo NordiskWSJ - The Wall Street Journal
Pfizer accuses Novo Nordisk of anticompetitive plot to stall Metsera deal in lawsuit - Reuters
Pfizer’s And Novo’s Competing Bids For Metsera Devolve Into Lawsuits, Name Calling - Citeline News & Insights
ACQUISITIONS & MERGERS NEWS: Pfizer sues Metsera and Novo Nordisk to halt their proposed merger - VitalLaw.com
Pfizer, Novo's Metsera war could redraw the map for obesity treatments - Axios
Pfizer Hits Novo Nordisk In Fed. Court Over $9B Metsera Deal - Law360
Metsera, Inc. Responds to Pfizer’s Litigation Claims - MSN
Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo - Investor's Business Daily
Pfizer Sues Novo, Metsera for Second Time in Brewing Deal War - Bloomberg.com
Pfizer Lawsuits Allege Novo Nordisk’s Bid to Buy Obesity Biotech Metsera is Anticompetitive, Illegal - MedCity News
Market Voices: Pfizer-Novo Nordisk legal battle; Trump on Zhao pardon - MSN
Pfizer Files Lawsuits Against Metsera and Novo Nordisk - Pharmaceutical Executive
Coinbase Said Web3 - Bloomberg.com
Pfizer sues to block Novo Nordisk bid for obesity drug maker Metsera - The Business Journals
Pfizer files US court challenge to Novo's bid for Metsera - MLex
FinCEN Offers Relief to Banks on ‘Overwhelming’ SARs Filings - PYMNTS.com
Pfizer files second lawsuit against Metsera, Novo Nordisk - whbl.com
Novo Nordisk’s Attempt to Buy Metsera is Anticompetitive, Says Pfizer in Second Lawsuit - TipRanks
Pfizer Q3 Earnings Preview: Results to test recovery hopes amid TrumpRx deal, Metsera dispute - MSN
Metsera rejects Pfizer litigation as attempt to lower acquisition price - Investing.com
Pfizer sues Novo, Metsera for second time in brewing deal war - Crain's New York Business
Metsera issues statement regarding Pfizer litigation and proposed acquisition By Investing.com - Investing.com UK
Metsera issues statement regarding Pfizer litigation and proposed acquisition - Investing.com
Novo Nordisk says Metsera bid won’t raise antitrust issues By Reuters - Investing.com
Pfizer Q3 Earnings Preview: Results to test recovery hopes amid TrumpRx deal, Metsera dispute (PFE:NYSE) - Seeking Alpha
Novo Nordisk says Metsera bid won't raise antitrust issues - Reuters
Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera - The Wall Street Journal
Pfizer Aligns With Trump on Drug Pricing In Its Bid for Biotech Metsera - Barron's
Novo Nordisk spokesperson says Pfizer's claims against co's Metsera offer is "without merit" - MarketScreener
Another Pfizer lawsuit to stop Novo bid for Metsera - The Pharma Letter
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech - CNBC
Pfizer Files Antitrust Lawsuit Against Metsera, Its Controlling Stockholders And Novo Nordisk - Nasdaq
Metsera Responds to Pfizer's Legal Action Amid Bid Interest from Novo Nordisk (NVO) - GuruFocus
Metsera to address Pfizer's litigation in court - MarketScreener
Metsera Issues Statement in Response to Litigation - Yahoo Finance
UPDATE: Pfizer Files Lawsuits Against Novo Nordisk, Metsera To Stop Rival Bid - BioSpace
How to build a custom watchlist for Metsera Inc.Market Growth Summary & Weekly Setup with High ROI Potential - newser.com
Is Metsera Inc. stock entering bullish territory2025 Dividend Review & Community Supported Trade Ideas - newser.com
Pfizer files two lawsuits to stop Novo's $9B buyout of Metsera - BioWorld MedTech
Is Metsera Inc. stock a safe investment in uncertain marketsTrade Entry Summary & Reliable Trade Execution Plans - newser.com
Pfizer files another lawsuit: Accuses Metsera owners of conspiring with Novo Nordisk - medwatch.com
Metsera falls after Pfizer files a second lawsuit against co and Novo - TradingView
How currency fluctuations impact Metsera Inc. stockJuly 2025 Summary & Proven Capital Preservation Tips - newser.com
Pfizer (PFE) Files Lawsuit Against Novo Nordisk Over Metsera Bid - GuruFocus
Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle - Benzinga
The Battle For Metsera Acquisition Heats Up As Pfizer Files A Second Lawsuit - MSN
Pfizer files second lawsuit to block Novo Nordisk’s $9bn Metsera bid - Financial Times
Pfizer files second lawsuit against Novo Nordisk, Metsera in battle over obesity startup - statnews.com
Pfizer sues Novo Nordisk and Metsera once againbid considered to restrict competition - MarketScreener
Why Metsera Inc. stock appeals to analystsEntry Point & Advanced Technical Signal Analysis - newser.com
Metsera Inc Stock (MTSR) Financials Data
There is no financial data for Metsera Inc (MTSR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):